Image Place holder

Monica S. Chatwal, MD

Specialty: Medical Oncology
Program: Satellite and Community Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center at International Plaza

Cancer Types Treated: Bladder Cancer , Kidney (Renal Cell) Cancer , Prostate Cancer , Testicular Cancer

Dr. Chatwal earned her MD at Florida State University School of Medicine. She completed her Internal Medicine Residency at Emory University School of Medicine, followed by a Hematology Oncology Fellowship at Moffitt Cancer Center and the University of South Florida Morsani College of Medicine. Dr. Chatwal’s clinical focus is the medical oncology management of patients with genitourinary malignancies, though she also brings to the practice her experience and interest in other solid malignancies. Her research focus will include clinical trials and outcomes in genitourinary malignancies. Dr. Chatwal also has a practical and research interest in the important issue of provider burnout. She has published data on approaches to improve individual resiliency, and will explore both individual and system-dependent approaches to help combat and alleviate this ongoing issue.

Education & Training

Participating Trials

A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Lirilumab; Nivolumab

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Condition: Genitourinary
Intervention: IMMU-132

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Chatwal MS, Tanvetyanon T. Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S208-S210. Pubmedid: 30393603. Pmcid: PMC6193911.
  • Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy. 2018 04;10(5):341-344. Pubmedid: 29473471.
  • Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Rev Respir Med. 2017 Oct;11(10):791-805. Pubmedid: 28786318.